Real-world Effectiveness of a COVID-19 Vaccine (BNT162b2) against SARS-CoV-2 Infection during the Omicron Variant Predominant Period among Thai Adolescents
DOI:
https://doi.org/10.59096/osir.v16i3.262998Keywords:
COVID-19 vaccine, adolescent, Omicron, SARS-CoV-2, vaccine effectivenessAbstract
This study assessed the real-world vaccine effectiveness (RVE) of a 2-dose schedule of BNT162b2 against the Omicron variant among Thai adolescents aged 12 to 18 in the Eastern Region. A test-negative matched 1:1 case-control design was conducted using nationwide records of RT-PCR tests and vaccination history. Cases were matched with controls by the specimen collection date and residential province. Conditional logistic regression was used to determine the RVE. From January to June 2022, when Omicron prevailed, 7,770 adolescents (3,758 detected and 4,012 undetected) were reported to the system. At the time of the RT-PCR test, 684 (14%), 295 (6%), 3,834 (78%), 104 (2%), and three adolescents had received no, one, two, three, and four doses of any COVID-19 vaccines, respectively. A total of 3,304 eligible adolescents with 2-dose of BNT162b2 with a median (interquartile range (IQR)) age of 16 (14–17) years were analyzed. The median (IQR) interval from the last vaccination to RT-PCR test was 91 (55–125) days. The age-adjusted RVE of BNT162b2 against infection was 22% (95% confidence interval (CI) 5–35%). The highest RVE was 71% (95% CI -9–92%), which occurred 15–29 days after vaccination. We therefore recommend that a booster dose be considered.
References
World Health Organization. Tracking SARS-CoV-2 variants [Internet]. Geneva: World Health Organization: [cited 2023 May 5]. <https://www.who.int/activities/tracking-SARS-CoV-2-variants>
Department of Medical Science, Ministry of Public Health. SARS-CoV-2 variants in Thailand [Internet]. Nonthaburi: Department of Medical Science: [cited 2023 Jun 20]. <https://www3.dmsc.moph.go.th/page-view/110>
Flores-Vega VR, Monroy-Molina JV, Jimenez-Hernandez LE, Torres AG, Santos-Preciado JI, Rosales-Reyes R. SARS-CoV-2: Evolution and emergence of new viral variants. Viruses. 2022 Mar 22;14(4):653. doi:10.3390/v14040653.
Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant. N Engl J Med. 2022 Apr 21;386(16): 1532–46. doi:10.1056/NEJMoa2119451.
Price AM, Olson SM, Newhams MM, Halasa NB, Boom JA, Sahni LC, et al. BNT162b2 protection against the Omicron variant in children and adolescents. N Engl J Med. 2022 May 19;386 (20):1899–909. doi:10.1056/NEJMoa2202826.
Chi WY, Li YD, Huang HC, Chan TEH, Chow SY, Su JH, et al. COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection. J Biomed Sci. 2022 Oct 15;29(1):82. doi:10.1186/s12929-022-00853-8.
She J, Liu L, Liu W. COVID-19 epidemic: Disease characteristics in children. J Med Virol. 2020 Jul;92(7):747–54. doi:10.1002/jmv.25807.
Bahl A, Mielke N, Johnson S, Desai A, Qu L. Severe COVID-19 outcomes in pediatrics: An observational cohort analysis comparing Alpha, Delta, and Omicron variants. Lancet Reg Health Am. 2023 Feb;18:100405. doi:10.1016/j.lana.2022.100405.
Anderson KN, Swedo EA, Trinh E, Ray C, Krause K, Verenden J, et al. Adverse childhood experiences during the COVID-19 pandemic and associations with poor mental health and suicidal behaviors among high school students- adolescent behaviors and experiences survey, United States, January-June 2021. MMWR Morb Mortal Wkly Rep 2022 Oct 14;71(41):1301–5. doi:10.15585/mmwr.mm7141a2.
Department of Disease Control, Ministry of Public Health. Thailand COVID-19 vaccines tracker [Internet]. Nonthaburi: Department of Disease Control; [cited 2023 Jun 20]. <https://ddc.moph.go.th/vaccine-covid19/pages/%E0%B8%A3%E0%B8%B2%E0%B8%A2%E0%B8%87%E0%B8%B2%E0%B8%99%E0%B8%84%E0%B8%A7%E0%B8%B2%E0%B8%A1%E0%B8%81%E0%B9%89%E0%B8%B2%E0%B8%A7%E0%B8%AB%E0%B8%99%E0%B9%89%E0%B8%B2%E0%B8%81%E0%B8%B2%E0%B8%A3%E0%B9%83%E0%B8%AB%E0%B9%89%E0%B8%9A%E0%B8%A3%E0%B8%B4%E0%B8%81%E0%B8%B2%E0%B8%A3%E0%B8%89%E0%B8%B5%E0%B8%94%E0%B8%A7%E0%B8%B1%E0%B8%84%E0%B8%8B%E0%B8%B5%E0%B8%99%E0%B9%82%E0%B8%84%E0%B8%A7%E0%B8%B4%E0%B8%94-19>. Thai.
Puenpa J, Rattanakomol P, Saengdao N, Chansaenroj J, Yorsaeng R, Suwannakarn K, et al. Molecular characterization and tracking of severe acute respiratory syndrome coronavirus 2 in Thailand, 2020-2022. Arch Virol. 2023 Jan 3;168(1):26. doi:10.1007/s00705-022-05666-6.
Department of Medical Sciences. SARS-CoV-2 variants in Thailand surveillance data by Department of Medical Sciences [dataset on the Internet]. Nonthaburi: Department of Medical Sciences: 2022 Oct 18 [cited 2023 May 5]. <https://dmsc.gdcatalog.go.th/dataset/sars-cov-2-variants/resource/>.
Department of Medical Sciences. National laboratory recording system [Internet]. Nonthaburi: Department of Medical Sciences: [cited 2023 Jul 1]. <https://service.dmsc.moph.go.th/reportcovid19/labsend/login/>
Ministry of Public Health. MOPH immunization center dashboard [Internet]. Nonthaburi: Ministry of Public Health: [cited 2023 Jul 1]. <https://cvp1.moph.go.th/dashboard>
National Center for Immunization and Respiratory Diseases, Division of Viral Diseases. Overview of Testing for SARS-CoV-2, the virus that causes COVID-19 [Internet]. Atlanta: U.S. Center for Disease Control and Prevention: [cited 2023 May 5] <https://www.cdc.gov/coronavirus/2019-ncov/hcp/testing-overview.html>
Poland GA, Ovsyannikova IG, Kennedy RB. SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. Lancet. 2020 Nov 14;396(10262):1595–606. doi:10.1016/S0140-6736(20)32137-1.
World Health Organization. Sample size calculator for evaluation of COVID-19 vaccine effectiveness (excel) [Internet]. Geneva: World Health Organization: 2021 Mar 17 [cited 2022 Jul 10]. <https://apps.who.int/iris/rest/bitstreams/1337428/retrieve>
Chiew CJ, Premikha M, Chong CY, Wei WE, Ong B, Lye DC, et al. Effectiveness of primary series and booster vaccination against SARS-CoV-2 infection and hospitalisation among adolescents aged 12-17 years in Singapore: a national cohort study. Lancet Infect Dis. 2023 Feb;23(2):177–82. doi:10.1016/S1473-3099(22)00573-4.
Frenck RW Jr, Klein NP, Kitchin N, Gurtman A, Absalon J, Lockhart S, et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. N Engl J Med. 2021 Jul;385(3):239–50. doi:10.1056/NEJMoa2107456.
Oliveira CR, Niccolai LM, Sheikha H, Elmansy L, Kalinich CC, Grubaugh ND, et al. Assessment of clinical effectiveness of BNT162b2 COVID-19 vaccine in US adolescents. JAMA Netw Open. 2022 Mar 1;5(3):e220935. doi:10.1001/jamanetworkopen.2022.0935.
Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant. N Engl J Med. 2022 Apr 21; 386(16):1532–46. doi:10.1056/NEJMoa2119451.
Iketani S, Liu L, Guo Y, Liu L, Chan JF, Huang Y, et al. Antibody evasion properties of SARS-CoV-2 Omicron sublineages. Nature. 2022 Apr; 604(7906):553–6. doi:10.1038/s41586-022-04594-4.
Liu L, Iketani S, Guo Y, Chan JF, Wang M, Liu L, et al. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature. 2022 Feb;602(7898):676–81. doi:10.1038/s41586-021-04388-0.
Fleming-Dutra KE, Britton A, Shang N, Derado G, Link-Gelles R, Accorsi EK, et al. Association of prior BNT162b2 COVID-19 vaccination with symptomatic SARS-CoV-2 infection in children and adolescents during Omicron predominance. JAMA. 2022 Jun 14;327(22):2210–9. doi:10.1001/jama.2022.7493.
Watanabe A, Iwagami M, Yasuhara J, Takagi H, Kuno T. Protective effect of COVID-19 vaccination against long COVID syndrome: A systematic review and meta-analysis. Vaccine. 2023;41(11): 1783–90. doi:10.1016/j.vaccine.2023.02.008.
Zambrano LD, Newhams MM, Olson SM, Halasa NB, Price AM, Boom JA, et al. Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA vaccination against multisystem inflammatory syndrome in children among persons aged 12-18 years - United States, July-December 2021. MMWR Morb Mortal Wkly Rep. 2022 Jan 14;71(2):52–8. doi:10.15585/mmwr.mm7102e1.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Outbreak, Surveillance, Investigation & Response (OSIR) Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
